PriceTargets.com logo

Graphite Bio - GRPH Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 03/7/2019 01:00 AM ET
+0 (0.00%)
Get New Graphite Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRPH

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Graphite Bio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for GRPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Graphite Bio. This rating has held steady since March 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/21/2023Royal Bank Of CanadaLower TargetSector Perform$28.00 ➝ $21.00
2/23/2023Bank of AmericaDowngradeNeutral ➝ Underperform$21.00 ➝ $14.00
2/23/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral$56.00 ➝ $21.00
2/23/2023CowenDowngradeOutperform ➝ Market Perform
2/23/2023CowenDowngradeOutperform ➝ Market Perform
2/3/2023Morgan StanleyLower TargetEqual Weight$42.00 ➝ $21.00
1/24/2023BTIG ResearchDowngradeBuy ➝ Neutral
1/18/2023Bank of AmericaDowngradeBuy ➝ Neutral$49.00 ➝ $21.00
1/6/2023Royal Bank Of CanadaLower TargetSector Perform$77.00 ➝ $28.00
1/6/2023Leerink PartnersDowngradeOutperform ➝ Market Perform$77.00 ➝ $14.00
1/6/2023BMO Capital MarketsDowngradeOutperform ➝ Market Perform$98.00 ➝ $49.00
12/27/2022Bank of AmericaLower Target$70.00 ➝ $56.00
9/15/2022Cantor FitzgeraldInitiated CoverageOverweight$84.00
8/12/2022Leerink PartnersReiterated RatingOutperform
7/15/2022Morgan StanleyLower TargetEqual Weight$56.00 ➝ $42.00
6/16/2022BMO Capital MarketsInitiated CoverageOutperform$84.00
4/14/2022BTIG ResearchInitiated CoverageBuy$126.00
3/22/2022Leerink PartnersLower TargetOutperform$238.00 ➝ $126.00
3/22/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$133.00 ➝ $56.00
2/17/2022Royal Bank Of CanadaInitiated CoverageSector Perform$77.00
11/14/2021Leerink PartnersReiterated RatingBuy$238.00
7/20/2021Morgan StanleyInitiated CoverageOverweight$245.00
7/20/2021Leerink PartnersInitiated CoverageOutperform$238.00
7/20/2021CowenInitiated CoverageOutperform
7/20/2021Bank of AmericaInitiated CoverageBuy$245.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Graphite Bio logo
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $13.89
Low: $3.18
High: $26.11

52 Week Range

Now: N/A

Volume

435,164 shs

Average Volume

282,405 shs

Market Capitalization

$185.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Graphite Bio?

The following Wall Street research analysts have issued stock ratings on Graphite Bio in the last twelve months:
View the latest analyst ratings for GRPH.

What is the current price target for Graphite Bio?

0 Wall Street analysts have set twelve-month price targets for Graphite Bio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Graphite Bio in the next year.
View the latest price targets for GRPH.

What is the current consensus analyst rating for Graphite Bio?

Graphite Bio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GRPH.

What other companies compete with Graphite Bio?

Other companies that are similar to Graphite Bio include Prime Medicine, Protalix BioTherapeutics, Inhibikase Therapeutics, Cortexyme and Invizyne Technologies. Learn More about companies similar to Graphite Bio.

How do I contact Graphite Bio's investor relations team?

The company's listed phone number is 650-484-0886 and its investor relations email address is [email protected]. The official website for Graphite Bio is www.graphitebio.com. Learn More about contacing Graphite Bio investor relations.